To make pricing accessible for early-stage startups, Fletch PMM intentionally removed time-consuming customer research. Instead, they extract founder knowledge through workshops, delivering a faster, more affordable, and still valuable engagement by focusing on organizing existing insights.

Focus groups and surveys are biased by pre-set questions. Ethnographic research—observing patients in their daily lives—uncovers their true hopes and needs, which can fundamentally transform a drug's development and go-to-market strategy.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

By releasing new software features weekly based on direct feedback from surgeons in the clinic, Andromeda has compressed the typical multi-year MedTech development cycle into weeks. This rapid, customer-centric improvement loop is shocking to the traditionally slow-moving medical industry.

Lancer Skincare's founder, a practicing dermatologist, provides a unique feedback channel. Daily patient interactions offer direct insights into product performance and identify market gaps for new products, a method more authentic and effective than traditional focus groups.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

MedTech companies often focus on pitching their solution's features. A more effective strategy for gaining trust and adoption is to first demonstrate a deep understanding of the user's (clinician, patient, admin) specific problems and pain points. This builds credibility and makes the solution itself more believable.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.

Iolyx Therapeutics' CEO notes the surprising capital efficiency of lean biotech. Her team advanced a drug from discovery through Phase 2 for approximately $20 million—an amount she could have easily spent on a single marketing campaign at Genentech. This highlights the operational leverage of focused, small teams.